KUPANDO Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$26.9M
- Investors
-
8
KUPANDO General Information
Description
Developer of a biotechnology platform designed to stimulate innate immunity to address unmet needs in cancer and infectious diseases. The company offers dual TLR agonist therapies with innate immune-training capabilities, enabling patients with oncology and infectious disease conditions to have improved access to novel immune-activating treatments.
Contact Information
Website
www.kupando.comCorporate Office
- Willy-Brandt-Platz 2
- 12529 Schönefeld
- Germany
Corporate Office
- Willy-Brandt-Platz 2
- 12529 Schönefeld
- Germany
KUPANDO Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC (Series A) | 18-Mar-2026 | $26.9M | Completed | Pre-Clinical Trials | ||
| 1. University Spin-Out | 13-Mar-2018 | Completed | Startup |
KUPANDO Comparisons
Industry
Financing
Details
KUPANDO Competitors (8)
One of KUPANDO’s 8 competitors is Bristol-Myers Squibb, a Corporation company based in Princeton, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb | Corporation | Princeton, NJ | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Amunix Pharmaceuticals | Formerly PE-Backed | South San Francisco, CA | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Pfizer Pakistan | Corporation | Karachi, Pakistan |
KUPANDO Patents
KUPANDO Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026139137-A1 | Crystalline forms of a tlr4 agonist and methods for preparing the same | Pending | 27-Dec-2024 | ||
| WO-2026139641-A1 | Crystalline forms of a tlr4 agonist and methods for preparing the same | Pending | 27-Dec-2024 | ||
| WO-2026139138-A1 | Pharmaceutical composition comprising tlr4 and tlr7 agonists | Pending | 27-Dec-2024 | ||
| WO-2026139642-A1 | Pharmaceutical composition comprising tlr4 and tlr7 agonists | Pending | 27-Dec-2024 | ||
| WO-2026139139-A1 | Pharmaceutical composition for medical use comprising tlr4 and tlr7 agonists | Pending | 27-Dec-2024 | A61K9/1075 |
KUPANDO Signals
KUPANDO Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Brandenburg Kapital | Venture Capital | Minority | ||
| CARMA FUND Management | Venture Capital | Minority | ||
| European Commission | Government | Minority | ||
| High-Tech Gründerfonds | Venture Capital | Minority | ||
| LifeCare Partners | Venture Capital | Minority |
KUPANDO FAQs
-
When was KUPANDO founded?
KUPANDO was founded in 2018.
-
Where is KUPANDO headquartered?
KUPANDO is headquartered in Schönefeld, Germany.
-
What is the size of KUPANDO?
KUPANDO has 8 total employees.
-
What industry is KUPANDO in?
KUPANDO’s primary industry is Drug Discovery.
-
Is KUPANDO a private or public company?
KUPANDO is a Private company.
-
What is KUPANDO’s current revenue?
The current revenue for KUPANDO is .
-
How much funding has KUPANDO raised over time?
KUPANDO has raised $26.9M.
-
Who are KUPANDO’s investors?
Brandenburg Kapital, CARMA FUND Management, European Commission, High-Tech Gründerfonds, and LifeCare Partners are 5 of 8 investors who have invested in KUPANDO.
-
Who are KUPANDO’s competitors?
Bristol-Myers Squibb, Gilead, Amunix Pharmaceuticals, Merck & Co., and Pfizer Pakistan are some of the 8 competitors of KUPANDO.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process